302
Participants
Start Date
October 26, 2022
Primary Completion Date
July 31, 2027
Study Completion Date
July 31, 2027
casdatifan
Administered as specified in the treatment arm
Cabozantinib
Administered as specified in the treatment arm
Zimberelimab
Administered as specified in the treatment arm
RECRUITING
Tisch Cancer Institute, Icahn Mount Sinai Hospital, New York
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Johns Hopkins Hospital, Baltimore
RECRUITING
University of Miami, Miami
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Sarah Cannon, Nashville
RECRUITING
Vanderbilt-Ingram Cancer Center, Nashville
RECRUITING
University of Louisville Brown Cancer Center, Louisville
RECRUITING
University Hospitals Cleveland Clinical, Cleveland
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Barbara Ann Karmanos Cancer Center, Detroit
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
Nebraska Cancer Specialists - Oncology Hematology West PC, Omaha
RECRUITING
Oschner Health, New Orleans
RECRUITING
South Texas Accelerated Research Therapeutics, LLC, San Antonio
RECRUITING
UCLA, Santa Monica
NOT_YET_RECRUITING
University of California at San Diego, San Diego
NOT_YET_RECRUITING
Medical Oncology Associates Summit Cancer Centers, Spokane
RECRUITING
Emory University, Atlanta
RECRUITING
Dana-Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Chris O'Brien Lifehouse, Camperdown
NOT_YET_RECRUITING
Box Hill Hospital, Melbourne
RECRUITING
Ashford Cancer Centre Research/ICON, Sydney
NOT_YET_RECRUITING
Macquarie University Hospital, Sydney
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Bundang Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
Lead Sponsor
Arcus Biosciences, Inc.
INDUSTRY